Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours

Overactivation of the mitogen-activated protein kinase (MAPK) pathway is an important driver of many human cancers. First line, FDA-approved therapies targeting MAPK signalling, which include BRAF and MEK inhibitors, have variable success across cancers, and a significant number of patients quickly...

Descripción completa

Detalles Bibliográficos
Autores principales: Paton, Emily L., Turner, Jacqueline A., Schlaepfer, Isabel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199609/
https://www.ncbi.nlm.nih.gov/pubmed/32411231
http://dx.doi.org/10.1155/2020/1079827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199609/
https://www.ncbi.nlm.nih.gov/pubmed/32411231
http://dx.doi.org/10.1155/2020/1079827

Ejemplares similares